Editorial Board

Our editorial board is comprised of clinical experts, organized primarily by disease focus. Most disease sites now have expert representation, but we are still looking for potential section or page editors. If you are interested, please feel free to contact us with any questions or inquiries, at [email protected].

Editor-in-Chief

Peter C. Yang, MD Boston, MA Twitter: Hem_Onc

Dr. Yang is board certified in Hematology and Medical Oncology; he practices at an academically affiliated institution in Massachusetts.

Deputy Editor

Jeremy L. Warner, MD, MS, FAMIA Vanderbilt University Nashville, TN Twitter: Hemoncwarner LinkedIn

Dr. Warner is board certified in Hematology, Medical Oncology, and Clinical Informatics; he practices at the Vanderbilt-Ingram Cancer Center. He is an associate professor at Vanderbilt University.

Section Editors

Breast Oncology
	Hermina Fernandes, MD, FACP Bismarck, ND	Dr. Fernandes is board certified in Medical Oncology and Hematology; she practices at the Edith Sanford Breast Center at Sanford Health. She is a clinical assistant professor at the University of North Dakota.
Dermatologic Oncology
	Elizabeth Buchbinder, MD Boston, MA LinkedIn	Dr. Buchbinder is board certified in Medical Oncology; she practices at the Dana-Farber Cancer Institute. She is an instructor at Harvard Medical School.
Endocrine Oncology
	Jeena M. Varghese, MBBS Houston, TX LinkedIn	Dr. Varghese is board certified in Internal Medicine and Endocrinology; she practices and is an assistant professor at the University of Texas MD Anderson Cancer Center.
Gastrointestinal Oncology
	Neeta K. Venepalli, MD, MBA Chicago, IL	Dr. Venepalli is board certified in Medical Oncology; she practices at UI Health. She is an associate professor at the University of Illinois at Chicago.
Genitourinary Oncology
	Eddy J. Chen, MD Boston, MA	Dr. Chen is board certified in Hematology and Medical Oncology; he practices at Massachusetts General Hospital. He is an instructor at Harvard Medical School.
Gynecologic Oncology
	Summer B. Dewdney, MD Chicago, IL	Dr. Dewdney is board certified in Gynecologic Oncology and Obstetrics and Gynecology; she practices at Rush Copley Medical Center. She is an assistant professor at Rush University.
Head & Neck Cancer
	Michael Gibson, MD, PhD Nashville, TN Twitter: mgibson21212 LinkedIn	Dr. Gibson is board certified in Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an associate professor at Vanderbilt University.
Neuro-Oncology
	Seema Nagpal, MD Palo Alto, CA	Dr. Nagpal is board certified in Neurology and UCNS certified in Neuro-Oncology; she practices at Stanford Health Care. She is a clinical assistant professor at Stanford University
Sarcoma
	James L. Chen, MD, MS Columbus, OH LinkedIn	Dr. Chen is board certified in Medical Oncology; he practices at an academically affiliated institution in the Columbus area.
Thoracic Oncology
	Travis Osterman, DO, MS Nashville, TN Twitter: TravisOsterman LinkedIn	Dr. Osterman is board certified in Medical Oncology and Clinical Informatics; he practices at Vanderbilt University Medical Center. He is an assistant professor at Vanderbilt University.
Acute Leukemias
	Martin W. Schoen, MD, MPH Saint Louis University St. Louis, MO	Dr. Schoen is board certified in Internal Medicine; he is a senior hematology/oncology fellow at Saint Louis University.
Myeloproliferative Neoplasms and Myelodysplastic Syndromes
	Sanjay R. Mohan, MD, MSCI Nashville, TN	Dr. Mohan is board certified in Hematology and Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an assistant professor at Vanderbilt University.
Aggressive Lymphomas
	Jose C. Villasboas Bisneto, MD Rochester, MN	Dr. Villasboas Bisneto is board certified in Hematology and Medical Oncology; he practices at the Mayo Clinic.
Indolent Lymphomas
	Sanjai Sharma, MD Visalia, CA	Dr. Sharma is board certified in Hematology and Medical Oncology; he practices at the Sequoia Regional Cancer Center.
Plasma Cell Dyscrasias
	Andrew J. Cowan, MD Seattle, WA LinkedIn	Dr. Cowan is board certified in Hematology and Medical Oncology; he practices at the Seattle Cancer Care Alliance. He is an assistant professor at the University of Washington.
T-cell and NK-cell neoplasms
	Unfilled	If you are interested, please feel free to contact us with any questions or inquiries, at [email protected].
Lymphoproliferative disorders
	Unfilled	If you are interested, please feel free to contact us with any questions or inquiries, at [email protected].
Histiocyte Disorders
	Ronald S. Go, MD Rochester, MN	Dr. Go is board certified in Hematology and Medical Oncology; he practices at the Mayo Clinic, where he is an associate professor.
Immuno-Oncology
	Meghan J. Mooradian, MD Boston, MA LinkedIn	Dr. Mooradian is board certified in Medical Oncology; she practices at Massachusetts General Hospital. She is an instructor at Harvard Medical School.
Pediatric Oncology
	Wayne H. Liang, MD, MS Birmingham, AL Twitter: WayneLiangMD LinkedIn	Dr. Liang is board certified in Pediatrics and board eligible in Pediatric Hematology-Oncology; he practices at Children's of Alabama. He is an assistant professor at UAB.
Transplant
	Aric C. Hall, MD Madison, WI Twitter: AricHall1	Dr. Hall is board certified in Hematology and Medical Oncology; he practices at UW Health. He is an assistant professor at the University of Wisconsin.
Classical Hematology
	Shruti Chaturvedi, MBBS, MSCI Baltimore, MD LinkedIn	Dr. Chaturvedi is board certified in Hematology and Medical Oncology; she practices at Johns Hopkins Medicine. She is an assistant professor at Johns Hopkins University.
	Benjamin Tillman, MD Nashville, TN	Dr. Tillman is board certified in Internal Medicine and board eligible in Hematology and Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an assistant professor at Vanderbilt University.

COI Disclosures

To be completed; please see our conflict of interest page for more details.

Name	Research funding	Other (honoraria, travel support, significant ownership interests, etc.)	Date of disclosure
Dr. Liang	Nothing to disclose	Nothing to disclose	Sept. 17, 2018
Dr. Tillman	Nothing to disclose	Nothing to disclose	Sept. 13, 2018
Dr. Warner	NIH; Vanderbilt University	ASCO; HemOnc.org	Sept. 17, 2018
Dr. Villasboas Bisneto	DoD; Lymphoma Research Foundation	Nothing to disclose	Sept. 13, 2018
Dr. Yang	Nothing to disclose	HemOnc.org; stock: Merck, Pfizer	Oct. 3, 2018